MedTrace Logo

Endometrial Advancement After Rec or u-HCG Triggering

NCT00953628 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2015-12-03

No results posted yet for this study

Summary

The purpose of this study is to investigate any potential advantages of replacing human chorionic gonadotropin (uhCG) with recombinant human chorionic gonadotropin (recHCG) for final oocyte maturation with regard to Ovarian hyperstimulation syndrome (OHSS)pathophysiology, endometrium receptivity and embryo quality and clinical pregnancy.

Conditions

Interventions

DRUG

10000 IU urinary HCG

bolus 10000 units for ovulation triggering

DRUG

250 mcg recombinant HCG

bolus 250 mcg for ovulation triggering in IVF patients

Sponsors & Collaborators

  • Merck Serono International SA

    collaborator INDUSTRY

  • Universitair Ziekenhuis Brussel

    lead OTHER

Principal Investigators

  • Paul Devroey, Professor · Professor or OB-GYN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
36 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-12-31
Completion
2008-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00953628 on ClinicalTrials.gov